Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 8/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6058724 | 1.00 | APP (0.69) | APPATMTTRDPP4ESR1 | |
| SCHEMBL19359002 | 0.95 | APP (0.70) | APPTTRDPP4SMN1; SMN2MET | |
| SCHEMBL19359001 | 0.95 | APP (0.70) | APPTTRDPP4SMN1; SMN2MET | |
| SCHEMBL2235002 | 0.89 | APP (0.78) | APPTTRDPP4ESR1LMNA | |
| SCHEMBL16794973 | 0.85 | TTR (0.66) | APPTTRDPP4CYP3A4FDPS | |
| SCHEMBL16794971 | 0.85 | TTR (0.66) | APPTTRDPP4CYP3A4FDPS | |
| SCHEMBL30807058 | 0.85 | TTR (0.66) | APPTTRDPP4CYP3A4FDPS | |
| SCHEMBL585288 | 0.84 | APP (0.59) | APPATMTTRDPP4ESR1 | |
| SCHEMBL585889 | 0.84 | APP (0.59) | APPATMESR1LMNASMN1; SMN2 | |
| SCHEMBL585888 | 0.84 | APP (0.59) | APPATMESR1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735262-A1 | PROCESS FOR PREPARING CINNAMIC ACIDS AND ALKYL ESTERS THEREOF | Honeywell International, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005105728-A1 | PROCESS FOR PREPARING CINNAMIC ACIDS AND ALKYL ESTERS THEREOF | HONEYWELL INTERNATIONAL INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050234261-A1 | Process for preparing cinnamic acids and alkyl esters thereof | HONEYWELL INTERNATIONAL INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234261-A1 | Process for preparing cinnamic acids and alkyl esters thereof | PCCA, LIPA, CA7 | APP 3929/4885ATM 1528/4885TTR 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.